Compounds > polyporenic acid c
Page last updated: 2024-12-11

polyporenic acid c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9805290
CHEMBL ID461276
SCHEMBL ID12830819
MeSH IDM0452578

Synonyms (18)

Synonym
CHEMBL461276
unii-8ec05ek77f
465-18-9
8ec05ek77f ,
SCHEMBL12830819
(16.alpha.)-16-hydroxy-24-methylene-3-oxolanosta-7,9(11)-dien-21-oic acid
lanosta-7,9(11)-dien-21-oic acid, 16.alpha.-hydroxy-24-methylene-3-oxo-
lanosta-7,9(11)-dien-21-oic acid, 16-hydroxy-24-methylene-3-oxo-, (16.alpha.)-
1283113-94-9
16.alpha.-hydroxy-24-methylene-3-oxo-5.alpha.-lanosta-7,9(11)-diene-30-oic acid
AKOS037514957
HY-N2993
F20728
(2r)-2-[(5r,10s,13r,14r,16r,17r)-16-hydroxy-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid
Q27270257
CS-0023649
MS-28980
(2r)-2-[(5r,10s,13r,14r,16r,17r)-16-hydroxy-3-keto-4,4,10,13,14-pentamethyl1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-5-isopropyl-hex-5-enoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID711420Cytotoxicity against human A549 cells2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID338911Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio2002Journal of natural products, Apr, Volume: 65, Issue:4
Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos.
AID338909Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA2002Journal of natural products, Apr, Volume: 65, Issue:4
Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos.
AID1427862Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay2016Journal of natural products, 11-23, Volume: 79, Issue:11
Cytotoxic Lanostanoids from Poria cocos.
AID1318680Cytotoxicity against C57BL/6 mouse BMDM assessed as decrease in cell viability at IC50 after 4 days in presence of RANKL/M-CSF by XTT assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Lanostane Triterpenes Isolated from Antrodia heteromorpha and Their Inhibitory Effects on RANKL-Induced Osteoclastogenesis.
AID1318678Inhibition of RANKL-induced C57BL/6 mouse BMDM differentiation into osteoclasts after 4 days in presence of M-CSF by TRAP assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Lanostane Triterpenes Isolated from Antrodia heteromorpha and Their Inhibitory Effects on RANKL-Induced Osteoclastogenesis.
AID338910Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA2002Journal of natural products, Apr, Volume: 65, Issue:4
Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos.
AID338908Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA2002Journal of natural products, Apr, Volume: 65, Issue:4
Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos.
AID711418Inhibition of TPA-induced tumor progression in mouse skin at 0.2 umol measured at week 202012Journal of natural products, Nov-26, Volume: 75, Issue:11
Lanostanoids from fungi: a group of potential anticancer compounds.
AID356317Antiinflammatory activity in mouse assessed as inhibition of TPA-induced ear edema at 400 nmol2003Journal of natural products, Aug, Volume: 66, Issue:8
Anti-inflammatory lanostane-type triterpene acids from Piptoporus betulinus.
AID1427863Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay2016Journal of natural products, 11-23, Volume: 79, Issue:11
Cytotoxic Lanostanoids from Poria cocos.
AID338907Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs by indirect immunofluorescence method relative to TPA2002Journal of natural products, Apr, Volume: 65, Issue:4
Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos.
AID1318679Inhibition of RANKL-induced C57BL/6 mouse BMDM differentiation into osteoclasts after 4 days in presence of M-CSF by TRAP staining-based light microscopy2016Journal of natural products, 06-24, Volume: 79, Issue:6
Lanostane Triterpenes Isolated from Antrodia heteromorpha and Their Inhibitory Effects on RANKL-Induced Osteoclastogenesis.
AID1427865Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2016Journal of natural products, 11-23, Volume: 79, Issue:11
Cytotoxic Lanostanoids from Poria cocos.
AID1427864Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay2016Journal of natural products, 11-23, Volume: 79, Issue:11
Cytotoxic Lanostanoids from Poria cocos.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.0110aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
glycyrrhetinic acid
[no description available]		2.0110cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
etoposide
[no description available]		3.1710beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
eburicoic acid
eburicoic acid: structure		3.1710
10-hydroxycamptothecin
[no description available]		3.1710pyranoindolizinoquinoline
ganoderic acid a
[no description available]		3.1710triterpenoid
ganoderiol f
ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source		3.1710triterpenoid
Ganodermanontriol
[no description available]		3.1710triterpenoidmetabolite
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.0110carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
poricoic acid a
poricoic acid A: from Poria cocos (Polyporaceae); structure in first source. poricoic acid A : A tricyclic triterpenoid isolated from Poria cocos.		2.4520dicarboxylic acid;
secondary alcohol;
tricyclic triterpenoid		fungal metabolite
poricoic acid g
poricoic acid G: from Poria cocos (Polyporaceae); structure in first source. poricoic acid G : A tricyclic triterpenoid isolated from Poria cocos.		3.5420dicarboxylic acid;
secondary alcohol;
tricyclic triterpenoid		fungal metabolite
trametenolic acid b
trametenolic acid B: from Trametes lactinea; structure in first source		3.1710triterpenoid
ganodermadiol
ganodermadiol: isolated from Ganoderma lucidum; structure given in first source. ganoderol B : A tetracyclic triterpenoid that is lanosta-7,9(11),24-triene which is substituted by hydroxy groups at positions 3 and 27. It has been isolated from several Ganoderma species.		3.17103beta-sterol;
primary allylic alcohol;
tetracyclic triterpenoid		antiviral agent;
fungal metabolite;
hepatoprotective agent
lucidenic acid a
lucidenic acid A: isolated from fruiting bodies of Ganoderma lucidum; structure in first source		3.1710triterpenoid
dehydroeburicoic acid
dehydroeburicoic acid: structure in first source		2.1310bile acid
ganoderic acid t
ganoderic acid T: down-regulates expression of both MMP-2 and MMP-9; isolated from Ganoderma lucidum; structure in first source		3.1710
ganoderic acid f
ganoderic acid F: isolated from Ganoderma lucidum; structure in first source		3.1710triterpenoid
inotodiol
inotodiol: structure in first source		3.1710
3,7-dioxolanosta-8,24-dien-26-oic acid
[no description available]		3.1710
ganoderic acid c2
ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source		3.1710triterpenoid
ganoderic acid y
ganoderic acid Y: has antiviral activity; isolated from Ganoderma lucidum; structure in first source		3.1710triterpenoid
7-oxo-ganoderic acid z
7-oxo-ganoderic acid Z: from the mushroom Ganoderma lucidum; structure in first source		3.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms, Brain
[description not available]		02.0110
Cancer of Colon
[description not available]		02.0110
Cancer of Kidney
[description not available]		02.0110
Granulocytic Leukemia
[description not available]		02.0110
Cancer of Lung
[description not available]		02.0110
Malignant Melanoma
[description not available]		02.0110
Cancer of Ovary
[description not available]		02.0110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.0110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0110
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.0110
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		02.0110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.0110
Anasarca
[description not available]		02.0110
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0110